Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,518.00
(
0.32%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
-0.89%
)
Bitcoin
73,344.12
(
-0.28%
)
News Focus
News Focus
Post# of 134
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

INV4

Send PM Follow Ignore
Followers 131
Posts 3756
Boards Moderated 6
Alias Born 07/04/2019

INV4

Member Level

Re: None

Monday, 05/18/2026 9:05:43 AM

Monday, May 18, 2026 9:05:43 AM

Post# of 134
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications

May 16, 2026

Clearmind Medicine (Nasdaq: CMND) signed a new research agreement with Yissum to fund a 12-month preclinical study of MEAI (CMND-100) with tirzepatide in diet-induced obese mice.

The study will assess combination and maintenance use in the fast-growing $50–66B incretin therapeutics market.

Link article

$CMND 🗞️

Don't invest what you can't afford to lose. Always do your own DD. INV4$

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent CMND News
More CMND News